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MaBACKGROUND Aging populations show higher incidences of myocardial infarction (MI) and heart failure (HF). Cardiac
remodeling post-MI leads to progressive impaired cardiac function caused by a disarray of several processes including
derailed autophagy. Microribonucleic acids (miRNAs) are known to be key players in cardiovascular disease but their
involvement in cardiac autophagy and aging is not well understood.
OBJECTIVES This study sought to identify new miRNA candidates that regulate cardiac autophagy and aging.
METHODS We exploited a high-throughput, ﬂuorescence-activated cell sorting-based green ﬂuorescent protein–LC3
detection method to measure the autophagic ﬂux in cardiomyocytes after transfection of a precursor miRNA library
consisting of 380 miRNAs. This was followed by a series of molecular and in vivo studies.
RESULTS Together with additional expression screenings, we identiﬁed miR-22 as an abundant and strong inhibitor of
the cardiac autophagy process. Cardiac miR-22 expression levels increased during aging of mice as well as in aging
neonatal cardiomyocytes in vitro by a P53-dependent mechanism. Inhibition of miR-22 in aging cardiomyocytes in vitro
activated autophagy and inhibited cellular hypertrophy. Pharmacological inhibition of miR-22 post-MI in older mice
activated cardiac autophagy, prevented post-infarction remodeling, and improved cardiac function compared with
control subjects. Interestingly, similar effects were less pronounced in younger mice with signiﬁcantly lower cardiac
miR-22 expression levels. In addition, circulating levels of miR-22 in 154 patients with systolic HF were highly associated
with early mortality.
CONCLUSIONS We concluded that miR-22 is an important regulator of cardiac autophagy and a potential therapeutic
target, especially in the older myocardium. Finally, circulating miR-22 provides prognostic information for HF patients,
highlighting miR-22 as a promising therapeutic and biomarker candidate for cardiovascular disorders. (J Am Coll Cardiol
2016;68:1557–71) © 2016 by the American College of Cardiology Foundation.m the aInstitute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany;
rvice de cardiologie, Pôle cardio-vasculaire et pulmonaire, Centre Hospitalier Régional et Universitaire de Lille, France–
iversité de Lille II, Lille, France; cInserm U1167, Institut Pasteur de Lille, Lille, France; dInstitute of Cardiovascular Regeneration,
ethe-University, Frankfurt am Main, Germany; eDepartment of Cardiology, Maastricht University, Maastricht, the Netherlands;
stitute of Experimental and Clinical Pharmacology and Toxicology, Albert-Ludwigs-Universität Freiburg, Freiburg im Breisgau,
rmany; gBIOSS Centre for Biological Signalling Studies, University of Freiburg, Freiburg, Germany; hExcellence Cluster
BIRTH, Hannover Medical School, Hannover, Germany; and the iNational Heart and Lung Institute, Imperial College, London,
ited Kingdom. This study was supported by the DGK Stipendium from the German Cardiac Society to Dr. Gupta. Dr. Gupta is
ded by the Deutsche Forschungsgemeinschaft (DFG) GU 1664-1-1 grant. Drs. Bauters, de Groote, and Pinet have received
ding from the Féderation Française de Cardiologie. Drs. Bauters, de Groote, Pinet, and T. Thum have received funding from
ropean Commission’s FP7 HOMAGE (grant agreement 305507) and the EU-project FIBROTARGET. Dr. de Windt is founder and
ckholder of Mirabilis Therapeutics, a miRNA company. Drs. Batkai and T. Thum are cofounders of a miRNA company (Cardior
armaceuticals GmbH). Dr. T. Thum has received funding from the IFB-Tx (BMBF 01EO1302), DFG TH 903/11-1, Fondation
ducq (MIRVAD), and the European Union–funded ERC Consolidator Grant LongHeart. All other authors have reported that
y have no relationships relevant to the contents of this paper to disclose.
nuscript received April 6, 2016; revised manuscript received June 21, 2016, accepted July 5, 2016.
ABBR EV I A T I ON S
AND ACRONYMS
Atg = autophagy-related gene
FACS = ﬂuorescence-activated
cell sorting
GFP = green ﬂuorescent
protein
LNA = locked nucleic acid
MI = myocardial infarction
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1558N oncommunicable diseases, notablycancer, diabetes, cardiovascularand neurological disorders, ac-
count for 65.5% of deaths (approximately
34.5 million) worldwide (1). Nearly 45% of
these deaths are due to cardiovascular dis-
ease (CVD), which remains the leading cause
of mortality worldwide (1). Myocardial infarc-
tion (MI) leading to chronic heart failure (HF)
is the most common form of CVD that is prev-alent in our society, and its incidence increases
dramatically with age. The loss of cardiac tissue and
ensuing impaired contractile function due to MI re-
sults in cardiac remodeling and cardiac hypertrophy,
ﬁbrosis, and altered autophagic activity. In older pa-
tients, all these processes are more pronounced (2),
although the molecular rationale remains unclear.SEE PAGE 1572Autophagy, a process that recycles cellular compo-
nents to maintain cellular homeostasis, is deregulated
in age-related disease, like HF (3). Indeed, cardiac-
speciﬁc deletion of the autophagy gene Atg5 in mice
leads to a progressive decline in function with age,
together with early appearance of other cardiac aging
hallmarks (cardiac hypertrophy and ﬁbrosis) eventu-
ally leading to premature death (4). Temporally
controlled deletion of Atg5 in adult mice also results in
cardiac dysfunction, hypertrophy, disorganized
sarcomere, mitochondria aggregation, and accumula-
tion of ubiquitinated proteins (5). Importantly, in the
case of MI, accumulation of p62 colocalized aggre-
somes has been observed in the infarct border zone and
in remote areas (6). Mammalian sterile 20-like kinase
1(Mst1/) mice do not show aggresome accumulation
and pathological left ventricular remodeling post-MI.
This phenotype is lost when Mst1/ are crossed with
Beclinþ/ mice, which show lower autophagic activity
(6). Therefore, the identiﬁcation of therapeutic targets
that modulate autophagy holds great promise as a new
treatment approach to cardiac remodeling and HF,
especially in older age.
Microribonucleic acids (miRNAs) are a class of
noncoding regulatory ribonucleic acid (RNA) mole-
cules of around 22 nucleotides in length; they exert
their function by complementary binding via their
seed sequence. In the past decade, miRNAs have been
identiﬁed as critical regulators of cardiac pathophys-
iology (7–9), but only a few miRNAs regulating cardiac
autophagy have been studied in detail (10). miRNA-
212/132 was demonstrated to have prohypertrophic
and antiautophagic effects in cardiomyocytes
via regulation of FoxO3a (8). Additionally, the
miRNAs miR-199a and -221 have been reported to beantiautophagic, thus promoting cardiac hypertrophy
(11,12).
We conducted a detailed functional study of 380
miRNAs to gain further insight into miRNA-dependent
regulation of cardiac autophagy. We identiﬁed miR-22
as a strong inhibitor of cardiac autophagy using
in vitro and preclinical in vivo models of MI in young
and older mice. Likewise, the prognostic importance
of circulating miR-22 was tested in a clinical cohort
of 198 patients with systolic heart failure.
METHODS
FLUORESCENCE-ACTIVATED CELL SORTING–BASED
AUTOPHAGY MEASUREMENTS AND LIBRARY SCREENING.
To measure autophagic ﬂux by a ﬂuorescence-
activated cell sorting (FACS)–based method, HL-1
cells were seeded in 48 well cell culture plates. The
next day, cells were transfected with precursor miR-
NAs together with Lipofectamine 2000 (Thermo
Fisher Scientiﬁc, Inc., Waltham, Massachusetts) and
transduced together with a green ﬂuorescent protein
(GFP)-LC3 adenovirus at a multiplicity of infection of
10; 48 h later, cells were trypsinized and ﬁxed, and
GFP intensity was measured with a Guava Easycyte
Flow Cytometer (EMD Millipore Corporation, Darm-
stadt, Germany). Data were analyzed with the FlowJo
software (FlowJo LLC, Ashland, Oregon), and mean
ﬂuorescence intensity (MFI) was calculated and
normalized to the control subjects. miRNA library
screening was performed with transfection of an
miRNA precursor library (4391437 AMO01T9H Mouse
– Pre-miR, Ambion, Thermo Fisher Scientiﬁc). Normal
medium was changed to starvation medium 8 h prior
to the endpoint, and thus ﬂux was measured in
response to starvation. Screening was performed in
single wells, whereas validation of the screen was
done in triplicates.
A detailed Methods section can be found in the
Online Appendix.
RESULTS
A FACS-based high-throughput assay measuring
GFP-LC3 was used to determine the autophagic ﬂux
in the HL-1 cardiac cell line (13). A lower GFP intensity
after starvation indicates activation of autophagy,
and an accumulation of GFP with thapsigargin, chlo-
roquine, and baﬁlomycin A1 treatment indicates
autophagy inhibition (Figures 1A and 1B, Online
Figures 1A to 1D). We performed a functional screen
of a miRNA precursor library (380 miRNAs) by using
this FACS-based strategy to identify miRNAs that
serve as autophagic regulators. We identiﬁed several
miRNAs that were functioning as inhibitors or
FIGURE 1 Identiﬁcation of Candidate miRNAs
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Fluorescence-activated cell sorting (FACS)–based green ﬂuorescent protein (GFP) measurements varied in normal, starved, and thapsigargin-treated HL-1 cells trans-
duced with GFP-LC3 adenovirus seen in both (A) a representative FACS plot and (B) GFP mean ﬂuorescence intensity (MFI). (C) Activators (blue dots) and inhibitors
(orange dots) were identiﬁed from precursor microribonucleic acid (miRNA) library screening. (D)MiR-22, -9, -204, -141, -200, and -211 were conﬁrmed as inhibitors and
miR-93 as an activator of autophagy, verifying the screening results. (E) miR-22 was identiﬁed among the top candidates that regulated autophagy and had relatively
higher cardiac expression. *p # 0.05; **p # 0.01; ***p # 0.001. Ct ¼ cycle threshold; miR ¼ microribonucleic acid.
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FIGURE 2 miR-22 Inhibits Cardiomyocyte Autophagy
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1561activators of autophagy (Figure 1C, Online Table 1).
Interestingly, miRNAs with the same seed sequence
often showed similar results (e.g., miR-141/200a or
-204/211) (Online Figure 1E). Certain miRNA hits were
individually validated (Figure 1D).
Next, we compared the identiﬁed autophagic
miRNA regulators with the cardiac miRNA expression
proﬁle and identiﬁed miR-22 to be highly abundant
and have a strong autophagy inhibitory function
(Figure 1E). miR-22 has been reported to be highly
enriched in cardiomyocytes compared with other
cardiac cell types (14); thus, we focused on this spe-
ciﬁc miRNA in the following analyses.
CARDIAC AUTOPHAGY, CARDIAC REGULATION,
AND miR-22. Autophagy is a complex, dynamic,
multistep process; therefore, potential autophagic
regulators should be validated by different methods
(15). The functional miRNA precursor screen and
validation experiments on the basis of LC3 degrada-
tion conﬁrmed that miR-22 functions as an autopha-
gic inhibitor. We next studied p62 in miR-22–modiﬁed
cardiomyocytes; p62 is an autophagic substrate that
shows a diffuse pattern of distribution at the basal
level, whereas cellular aggregation is observed during
autophagic inhibition (15). Indeed, overexpression of
miR-22 in HL-1 cells increased aggregated p62
(Figures 2A to 2C), whereas miR-22 inhibition reversed
this effect (Online Figures 2A to 2C). As proof of
concept, another strong autophagic inhibitor, miR-9
derived from the screen, also led to accumulated
punctated p62 (Figures 2A to 2C), again reversed by
miR-9 inhibition (Online Figures 2A to 2C).
We next conﬁrmed our ﬁndings from the HL-1 cell
line in primary cardiomyocytes; here, we counted the
autophagic puncta (GFP-LC3) after miR-22 over-
expression in neonatal rat cardiomyocytes. Cardio-
myocytes with miR-22 overexpression showed fewer
autophagic puncta, conﬁrming miR-22’s inhibitory ef-
fects (Figures 2D to 2F). Also, accumulation of p62 pro-
tein levels was shown after pre–miR-22 transfection in
neonatal rat cardiomyocytes (Figure 2G). Thus, using
different methods, we demonstrated that miR-22 is
a strong autophagic inhibitor in cardiomyocytes.
miR-22 has been reported as a pro-hypertrophic
miRNA (14,16,17). Its inhibition abolished cardiac
hypertrophy, whereas its overexpression resulted in
massive hypertrophy (14,16). Previously, our group
reported miR-22 to be induced during aging in murine
hearts (18). Cardiac miR-22 expression levels were
conﬁrmed in mice of different ages, from 4 days to 1.7
years. We found a 3-fold up-regulation at 3 months of
age compared with younger control subjects followed
by a further gradual increase with age (Figure 3A).
Furthermore, miR-22 expression increased in humanmyocardium with age (Figure 3B), with human fetal
hearts showing signiﬁcantly lower levels of miR-22
compared with adults (Figure 3C). Apart from real-
time measurements, RNA sequencing of miR-22
showed a progressive increase from 12 to 52 to 104
weeks during natural aging in murine hearts
(Figure 3D). Similar to natural aging, we used an
accelerated aging model (Lamin A/C heterozygous
mice), where the hearts also had higher sequencing
reads for miR-22 already at mid-age (Figure 3D). We
then checked whether the aging-mediated miR-22
induction was restricted to cardiomyocytes. Inter-
estingly, miR-22 was speciﬁcally increased in car-
diomyocytes from older hearts, whereas no change
was evident in other cardiac cell population
(Figure 3E). Collectively, these results conﬁrmed in-
duction of miR-22 during cardiac aging.
A decline in cardiac autophagic activity with age
was previously reported (4), leading to our hypothe-
sis that miR-22 regulated the decrease in autophagy
during aging. To study the effects of miR-22 on car-
diac aging and autophagy, we used an established
in vitro cardiomyocyte aging model (19) where we
cultivated neonatal rat cardiomyocytes for 2 weeks
and compared older to early (day 3) cultured car-
diomyocytes. miR-22 was signiﬁcantly up-regulated
in old compared to young cardiomyocytes
(Figure 3F). Interestingly, the autophagic substrate
p62 was also up-regulated in old (vs. young) car-
diomyocytes, conﬁrming cardiac autophagic inhibi-
tion with age (Figures 3G and 3H). Next, we inhibited
miR-22 by a locked nucleic acid (LNA)–based anti-miR
approach (Online Figure 3A). Inhibition of miR-22 in
aging cardiomyocytes led to partial restoration of
myocardial autophagy, demonstrated by lower levels
of p62 (Figures 3G and 3H). A culture of car-
diomyocytes for 2 weeks resulted in cellular hyper-
trophy, which was partially inhibited by miR-22
silencing, suggesting that miR-22 inhibition can
reverse some of the aging effects in cultured car-
diomyocytes (Online Figures 3B to 3D). Another
miRNA, miR-9, identiﬁed from the screen as an
autophagic inhibitor, also exerted pro-hypertrophic
effects in neonatal rat cardiomyocytes, showing an
opposite relation of autophagy and hypertrophy
(Online Figure 4).
UPSTREAM REGULATORS OF miR-22. We searched
for potential upstream regulators of miR-22 and
identiﬁed p53 as a transcriptional activator of miR-22
(20). To determine whether p53 is a direct inducer of
miR-22 during aging, we treated neonatal rat car-
diomyocytes with the p53 inhibitor piﬁthrin-alpha,
which prevented the miR-22 induction during aging
of cardiomyocytes (Figure 3I). Furthermore, small
FIGURE 3 miR-22 Up-Regulation During Cardiac Aging
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1563interfering RNA-mediated inhibition of p53 in aging
cardiomyocytes partially decreased miR-22 expres-
sion levels (Online Figures 5A and 5B), conﬁrming a
direct role of p53 in miR-22 induction during
myocardial aging. For conﬁrmation, we analyzed the
effect of piﬁthrin-alpha on cardiac autophagy.
Indeed, piﬁthrin-alpha induced autophagy at basal
levels, and overexpression of miR-22 prevented
piﬁthrin-alpha activated autophagy (Figures 3J and
3K). Furthermore, piﬁthrin-alpha completely pre-
vented the development of cellular hypertrophy in
aging cardiomyocytes, which was only partially
rescued by miR-22 overexpression (Online Figures 5C
to 5E). Thus, p53 appears to be an upstream inducer of
miR-22 during aging.
THERAPEUTIC POTENTIAL OF miR-22 INHIBITION.
On the basis of these in vitro results, we speculated
that inhibition of miR-22 in vivo would be beneﬁcial
for the treatment of age-related cardiac diseases (a
speciﬁc situation where both miR-22 expression is
increased and cardiac autophagy impaired). Thus, we
inhibited miR-22 in both older (age 10 to 11 months)
and juvenile (age 9 weeks) mice post-MI. miR-22 was
successfully down-regulated in both border and
remote myocardium of older infarcted mice after LNA
targeting miR-22 treatment compared with LNA-
scramble control treated subjects (Online Figures 6A
and 6B). Echocardiographic assessment of cardiac
function showed a reduced ejection fraction in mice
with MI compared to sham, which was restored in the
LNA–anti-miR-22–treated older group, depicting a
beneﬁcial effect of miR-22 inhibition post-MI
(Figure 4A). Additionally, the Tei index and cardiac
output were impaired after MI but restored in older
animals with MI treated with the miR-22 inhibitor
(Figures 4B and 4C). Systolic volume was increased
post-MI, which again was attenuated by LNA–anti-
miR-22 treatment (Figure 4D).
We next performed speckle tracking strain imaging
to evaluate myocardial wall motion post-MI. Regional
evaluation of peak longitudinal strain rate showed aFIGURE 3 Continued
(A) miR-22 gradually increased during aging in murine hearts (n ¼ 4 to 8)
with those <40 years of age and adult compared with fetal myocardium (
expression levels in accelerated aging model LMNAþ/ hearts. (E) In frac
Increased miR-22 levels in aging cardiomyocytes in vitro. p62 levels in y
control or LNA 22 are (G) signiﬁcantly different in the complete dataset a
22 in aging cardiomyocytes. Piﬁ-a activated autophagy in HL-1 cells as se
restored by overexpression of miR-22. *p# 0.05, **p# 0.01, ***p# 0.0
Figures 1 and 2.signiﬁcant decrease in the posterior apex of hearts
post-infarction that was signiﬁcantly improved with
miR-22 inhibition; other cardiac regions showed
similar trends (Figure 4E). Average peak longitudinal
strain rate of the complete myocardium was signiﬁ-
cantly recovered in mice with miR-22 inhibition
compared with scrambled control subjects (Online
Figure 6C). Global longitudinal strain was also lower
in infarct animals compared with sham control ani-
mals but was signiﬁcantly improved in older animals
treated with LNA–anti-miR-22 (Figure 4F). At the
histological level, a signiﬁcant increase in car-
diomyocyte size was evident in remote regions of
infarcted hearts treated with LNA-scramble compared
with sham, whereas LNA–anti-miR-22–treated mice
were protected from development of cellular car-
diomyocyte hypertrophy, suggesting improved car-
diac remodeling (Figures 4E to 4G). Taken together,
these results showed that miR-22 inhibition is bene-
ﬁcial for the restoration of cardiac function post-MI in
older mice.
As miR-22 is increased in old myocardium and
signiﬁcantly lower in younger mice (Figure 5A), we
also tested potential beneﬁcial effects of miR-22 in-
hibition in young mice post-MI. For this, we per-
formed MIs in juvenile mice and inhibited miR-22
similar to the older mouse study. Real-time poly-
merase chain reaction analysis showed inhibition of
miR-22 after LNA–anti-miR-22 treatment in myocar-
dium compared to mice receiving the scrambled
control (Figure 5B). Echocardiographic assessment
indicated lesser improvement in ejection fraction and
cardiac output in the LNA–anti-miR-22–treated group
compared with scrambled-control–treated mice
(Figures 5C and 5D). Other parameters such as systolic
volume and Tei index were not signiﬁcantly altered
by miR-22 inhibition in young mice post-MI
(Figures 5E and 5F). Similar to the standard echocar-
diography data, strain imaging also showed no im-
provements with miR-22 blockade in young MI mice.
Global longitudinal strain (Figure 5G) and global. (B) Higher levels of miR-22 expression were seen in human hearts >40 years of age compared
C). (D) Sequencing of miR-22 showed a gradual increase during natural cardiac aging and higher
tionated young and old hearts, cardiomyocyte restricted induction of miR-22 during aging. (F)
ounger and older cardiomyocytes treated with either locked nucleic acid (LNA)-scramble (Scr)
nd (H) visibly different in the representative western blot. (I) Piﬁthrin-a (Piﬁ-a) repressed miR-
en by lower GFP intensity via (J) a representative FACS plot and (K) GFP MFI; GFP intensity was
01. RNA ¼ ribonucleic acid; SnoRNA ¼ small nucleolar ribonucleic acid; other abbreviations as in
FIGURE 4 Pharmacological Inhibition of miR-22 in Older Mice Post-MI
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1565longitudinal peak strain rate (Figure 5I) were signiﬁ-
cantly lower in hearts with MI versus sham, but were
only slightly improved by LNA–anti-miR-22 treat-
ment. Analysis of regional wall motion measured by
peak strain rate showed no signiﬁcant improvement
in any myocardial region in hearts with miR-22 inhi-
bition compared with scramble control subjects
(Figure 5H).
Evaluation of cardiomyocyte size found increased
cell size in the infarcted heart compared with sham,
but no signiﬁcant effect on cardiomyocyte cell
size in LNA–anti-miR-22–treated animals (Figures 5J
to 5L). After picrosirius red staining, we found
ﬁbrosis was higher in older sham compared with
younger sham hearts (Online Figures 6D and 6E),
but no increased ﬁbrosis was evident 2 weeks post-
MI either in young or old hearts treated with
LNA scramble or with LNA–anti-miR-22 (Online
Figures 6F and 6G). Per these results, young mice
had a signiﬁcantly weaker response to miR-22
therapy, whereas older mice, which show higher
cardiac miR-22 expression levels, had a very strong
beneﬁcial response, demonstrating signiﬁcant age-
dependent effects of a cardiac miRNA therapy on
the basis of age-dependent expression of miR-22
levels.
DOWNSTREAM TARGETS OF miR-22. To identify
downstream targets responsible for beneﬁcial effects
of miR-22 inhibition, we listed all validated targets of
miR-22 and identiﬁed 20 candidate genes known to
regulate both cardiac biology and autophagy
(Figure 6A). Expression levels of the selected candi-
dates were analyzed in older MI hearts, and Akt3,
Hdac6, and Ppara were signiﬁcantly increased with
miR-22 inhibition (Figure 6B, Online Figure 7A). Ppara
was selected for further studies due to its high cardiac
expression levels. In contrast to aging myocardium,
no changes were observed in Ppara expression
levels in young mice with miR-22 inhibition post-MI,
which suggests Ppara may be a downstream medi-
ator responsible for the beneﬁcial effects of miR-22FIGURE 4 Continued
Decline in cardiac function after myocardial infarction (MI) assessed b
and (D) systolic volume, was restored in LNA–anti-miR-22–treated mi
showed improved regional (E) peak longitudinal strain rate (PLSR) an
diomyocyte cross-sectional area in infarcted hearts compared with sha
distribution of area measurements and (I) stained segments. n ¼ 5 sh
*p # 0.05; **p # 0.01; ***p # 0.001. AA ¼ anterior apex; AB ¼ anter
other abbreviations as in Figures 1 and 3.inhibition, speciﬁcally in older mice (Figure 6C). The
peroxisome proliferator-activated receptor-alpha
(PPAR-a) agonist GW7647 was reported to activate
autophagy in the liver (21), but the effects of PPAR-a
activity on cardiac autophagy have not yet been
studied. We treated HL-1 cells with GW7647; they
responded with a moderate activation of autophagy
as depicted by increased GFP degradation. This was
prevented after overexpression of miR-22, suggesting
a direct involvement of PPAR-a in cardiac autophagy
regulation (Figures 6D and 6E). Furthermore, in vivo
myocardial levels of the autophagic substrate p62
were lower after miR-22 inhibition, revealing activa-
tion of autophagy (Figure 6F). Although miR-22 inhi-
bition prevented cardiac hypertrophy and activated
autophagy, a direct correlation of both hypertrophy
and autophagy remained inconclusive. To determine
whether hypertrophic inducers may affect auto-
phagy, we implanted phenylephrine (PE) and
isoproterenol (ISO)–containing minipumps in adult
mice for 1 week to induce cardiac hypertrophy
in vivo. In that scenario, p62 accumulated in PE/ISO–
treated hearts compared with control hearts
(Figure 6G). Similarly, neonatal rat cardiomyocytes
treated with PE/ISO showed an accumulation of p62,
conﬁrming inhibition of autophagy with hypertro-
phic agonists (Online Figures 7B and 7C). miR-22
deletion was reported to impede cardiac hypertro-
phy in calcineurin transgenic hearts, another model
of massive hypertrophy (14). We thus determined
the levels of p62 in calcineurin transgenic and
wild-type hearts, identifying an accumulation of
p62, which conﬁrmed reduced autophagic activity
and provided a potential link between hyper-
trophy and impaired cardiac autophagic activity
(Figure 6H).
CIRCULATING miR-22 AS A PROGNOSTIC BIOMARKER.
Our studies of intracellular miR-22 levels in vitro and
in vivo prompted us to also assess levels of circulating
miR-22 in patients with systolic HF from ischemic
and nonischemic origin. Indeed, the existence ofy echocardiography, as measured by (A) ejection fraction, (B) Tei index, (C) cardiac output,
ce. Strain imaging of hearts by Vevostrain (Fujiﬁlm VisualSonics, Toronto, Ontario, Canada)
d (F) global longitudinal strain (GLS) with miR-22 inhibition post-MI. (G) Increased car-
m was absent in LNA–anti-miR-22–treated hearts, which was reﬂected in (H) the frequency
am; n ¼ 8 to 10 LNA-scramble; and n ¼ 10 LNA–anti-miR-22. Scale bar ¼ 100 mm.
ior base; AM ¼ anterior mid; PA ¼ posterior apex; PB ¼ posterior base; PM ¼ posterior mid;
FIGURE 5 Inhibition of miR-22 in Young Mice Post-MI
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1567tissue-free, circulating miRNAs and other RNAs in
body ﬂuids have suggested the possibility of devel-
oping noncoding RNA biomarkers for heart diseases
(22,23). miR-22 had been reported as cardiomyocyte-
enriched miRNA, playing a very important role in
cardiovascular pathophysiology (14,16). We studied
the association of circulating miR-22 levels with
the prognosis of HF patients in 154 patients in a
case/control setting (patient characteristics are sum-
marized in Online Table 2). The patients who died
during the 3-year follow-up had signiﬁcantly higher
New York Heart Association functional class, brain
natriuretic protein, and creatinine levels, and lower
peak VO2.
The mean normalized delta cycle threshold (dCt)
value for miR-22 was 4.11  0.91 (range: 6.57
to 1.94). There was no association between age and
circulating miR-22 levels (r2 ¼ 0.0128; p ¼ 0.162). The
levels of miR-22 were similar in ischemic HF (4.19 
0.87) and nonischemic HF (3.98  0.94; p ¼ 0.159).
miR-22 levels at the time of prognostic evaluation
were higher in case patients than control subjects
(3.80  0.94 vs. 4.42  0.74; 1.54-fold change;
p < 0.0001) (Figure 7A). In a model adjusting for age,
sex, New York Heart Association functional class, HF
etiology, serum creatinine, left ventricular ejection
fraction, brain natriuretic protein, and peak VO2,
miR-22 levels remain independently associated with
cardiovascular mortality. Compared with patients in
the ﬁrst quartile of miR-22 levels, patients in the third
and fourth quartiles had signiﬁcantly increased car-
diovascular mortality (Figure 7B). The prognostic as-
sociation of miR-22 levels was observed in ischemic
HF (cases: 3.89  0.92; control subjects: 4.48 
0.72; p ¼ 0.0009) and nonischemic HF (cases: 3.68 
0.97; control subjects: 4.33  0.78; p ¼ 0.0054).
Similarly, the association was observed in patients
>60 years of age (cases: 3.89  0.94; control
subjects: 4.44  0.66; p ¼ 0.0036) and in
patients #60 years of age (cases: 3.71  0.94; control
subjects: 4.40  0.83; p ¼ 0.0012). To identify the
probable source of circulating miR-22, we assessedFIGURE 5 Continued
(A)Myocardial expression levels of miR-22 were higher in old mice (age 1
miR-22 compared with LNA-scramble (scr). Echocardiographic analysis o
deteriorated cardiac function with infarction and minor improvements w
infarcted hearts compared with sham. (I) Global longitudinal strain (GLS)
(J) Cardiac cross-sectional measurements with wheat germ agglutinin sta
(K) the frequency distribution of area measurements and (L) stained seg
100 mm. *p # 0.05; ***p # 0.001. Abbreviations as in Figures 1, 3, andthe expression of miR-22 in different mouse organs
and found miR-22 to be highly expressed in muscle
tissue followed by aorta, lung, and liver (Figure 7C).
Thus, the source of higher circulating miR-22 likely is
the heart together with other organs, such as the
liver.
DISCUSSION
We demonstrated that miR-22 is a key regulator of
cardiac autophagy and shows therapeutic potential as
a novel target to treat post-infarct remodeling, espe-
cially in older mice. Balanced autophagic activity is
necessary for the healthy functioning of the heart.
Autophagy is reported to be regulated by several Atg
genes, whereas only some miRNAs are known to
control myocardial autophagy (10). We performed a
large functional screening approach for miRNAs to
identify new regulators of myocardial autophagy. In
our phenotypic functional miRNA screening, we
found miR-22 to be a strong inhibitor of cardiac
autophagy. miR-22 was increased during aging in
murine and human myocardium. Our results showed
that miR-22 inhibition post-infarction led to
improved cardiac function and inhibited cardiac
remodeling in older mice (Central Illustration) but not
young mice, correlating with the observation that
miR-22 expression levels are high in older but not
young myocardium. Thus, our results demonstrated
that pharmacological inhibition of miR-22 is of ther-
apeutic relevance especially in older myocardium.
Several studies report miR-22 as a pro-
hypertrophic miRNA, and permanent deletion of
miR-22 blunted hypertrophy induced by various car-
diac stress but led to cardiac dilation (14,16,17). Pre-
vious studies have investigated miR-22 knockout
mice submitted to various forms of cardiac stress,
such as pressure overload, isoproterenol infusion, or
calcineurin overexpression (14,24). Our study was the
ﬁrst to evaluate the effect of pharmacological inhibi-
tion of miR-22 in an MI model. Moreover, the MI
performed in older animals in our study is more0 to 11 months) relative to young mice (age 9 weeks). (B) LNA–anti-miR-22 signiﬁcantly reduced
f (C) ejection fraction, (D) cardiac output, (E) systolic volume, and (F) Tei index showed
ith miR-22 inhibition. (G) Global and (H) regional PLSR showed decrease in wall motion of
also decreased upon myocardial infarction with no improvement in the LNA–anti-miR-22 group.
ining showing increased area in infarcted hearts compared with sham; this was also reﬂected in
ments. n ¼ 5 to 6 sham; n ¼ 11 to 12 LNA-scramble; and n ¼ 11 LNA–anti-miR-22. Scale bar ¼
4.
FIGURE 6 Downstream Effectors of miR-22
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FIGURE 7 Prognostic Effect of miR-22 Levels in Chronic Heart Failure
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(A) Comparative scatterplots showing normalized miR-22 levels at inclusion according to outcome (no cardiovascular death vs. cardiovascular
death) during 3-year follow-up. (Mean delta cycle threshold [dCt] values calculated as mean Ct value of normalizer average  Ct value of miR-
22; p value calculated by unpaired Student t test.) Orange lines ¼ respective medians; blue circles ¼ individual patients. (B) Adjusted odds
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(quartile 1: 6.57 to 4.69; quartile 2: 4.68 to 4.03; quartile 3: 4.02 to 3.39; quartile 4: 3.38 to 1.94). (C) MiR-22 expression levels
in different organs of the adult mice.
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1569relevant to clinical settings, as hospitalization rates
with cardiovascular abnormalities are signiﬁcantly
higher in older people (25).
We showed that miR-22 inhibition activated
cardiac autophagy, leading to improved function
post-MI. Similarly, Ruozi et al. (26) discovered that
ghrelin improves cardiac function after MI by acti-
vating myocardial autophagy. Another study also
demonstrated the beneﬁcial effect of autophagic
activation by rapamycin post-MI (27). Taken together,
these studies illustrated the beneﬁts of autophagic
activation post-infarction.
Among several targets of miR-22, we provided new
evidence for de-repression of PPAR-a by miR-22
inhibition, speciﬁcally in older hearts. A moderateactivation of autophagy has been seen with PPAR-a
agonist, indicating that PPAR-a is at least partially
responsible for the autophagic inhibitory function of
miR-22. Apart from the intracellular function of
miR-22, we found that circulating levels of miR-22
can predict mortality in HF patients. Higher levels
of miR-22 showed a signiﬁcant association with
cardiovascular mortality, reﬂecting its prognostic
potential.
STUDY LIMITATIONS. A multifactorial process, car-
diac aging includes several cell types. Our study
cannot rule out the possible effect of LNA-mediated
miR-22 inhibition on other cell types; thus, the
beneﬁcial effects we identiﬁed may be due to a
CENTRAL ILLUSTRATION Therapeutic Potential of miR-22
Gupta, S.K. et al. J Am Coll Cardiol. 2016;68(14):1557–71.
Microribonucleic acid-22 (miR-22) is increased in aging hearts and was shown in this study to regulate cardiac autophagy. Antisense nucleotide-based pharmacological
inhibition via locked nucleic acid (LNA) of miR-22 post–myocardial infarction in aging mice resulted in cardiac functional beneﬁts. PPAR ¼ peroxisome proliferator-
activated receptor.
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ciﬁc. Another limitation of our study was the in vitro
aging model, which is not completely similar to
the in vivo model. However, similar results from
both models conﬁrmed miR-22 to be a pro-aging
candidate.
CONCLUSIONS
We have reported a new functional role of miR-22 in
older myocardium, putting forward a new prognostic
tool for patients with MI and a treatment strategy onthe basis of miR-22 inhibition for elderly individuals
with myocardial infarction.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Inhibi-
tion of a noncoding older-cardiomyocyte–enriched
microRNA, miR-22, attenuated adverse remodeling and
improved cardiac function in an animal model of MI in
older but not younger mice, and circulating miR-22 levels
predicted death in patients with systolic HF.
TRANSLATIONAL OUTLOOK: Future studies should
explore the potential roles of miR-22 as both a prognostic
marker in patients with HF and a treatment target for
elderly patients with MI.
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APPENDIX For an expanded Methods section
as well as supplemental ﬁgures and tables,
please see the online version of this article.
